Guangshengtang 20cm up limit, Chinese medicine 2 plates... On the 16th, the pharmaceutical sector became active again

【Pharmaceutical Network Pharmaceutical Stock Market】 On December 16, the intraday Chinese medicine sector was active again, Guangshengtang hit the 20cm price limit, China Pharmaceutical achieved 2 consecutive boards, Lingkang Pharmaceutical, Zhongsheng Pharmaceutical, Xinhua Pharmaceutical and other stocks rose to the limit, Shutai Shen, Hengdi Pharmaceutical, Xinhua Pharmaceutical, etc.
rose by more than 9%.

On the morning of December 16, Guangshengtang quickly raised the price limit board, and now reported 48.
6 yuan / share, the turnover was enlarged to 630 million yuan, and the total market value was 7.
74 billion yuan
。 On the news, on December 15, Guangshengtang issued an announcement that GST-HG171, an innovative drug of 3CL protease inhibitors of subsidiary Guangsheng Zhonglin, recently obtained the team leader's approval from the ethics committee of the First Affiliated Hospital of Guangzhou Medical University and the Third People's Hospital of Shenzhen on the initiation of phase II/III clinical trials, marking that the key registered clinical study of phase II/III seamless design of the company's GST-HG171 project has been fully and substantially launched
.
Data show that 3CL protease inhibitors can achieve the effect
of destroying viruses by interfering with the replication of the virus itself.
At present, oral 3CL protease inhibitors in clinical phase 2/3 and later in China also include RAY1216 of Zhongsheng Pharmaceutical and SIM0417
of Simcere Pharmaceutical.
Guangshengtang also reminded that the GST-HG171 project needs to complete clinical research and be approved by the national drug review department before it can be marketed, and the future epidemic situation and clinical research progress, research results and review and approval results are uncertain
.
The company will carry out relevant clinical trials as soon as possible in strict accordance with the requirements of the approval documents, comprehensively investigate the effectiveness of the drug, and apply for production registration approval in accordance with laws and regulations
.
At the same time, the company will promote the external financing and cooperation of innovative drug subsidiaries, seek to jointly develop overseas markets, and strive to make more contributions
to the fight against the epidemic.
At 9:26 on December 16, China Pharmaceutical opened at 20.
3 yuan, and the current closed order is 343891 lot, equivalent to 698 million yuan
.
Up to now, the transaction has reached 103 million yuan, with a turnover rate of 0.
34%.

On the news, China National Pharmaceutical announced on the evening of December 14 that the company signed an import distribution agreement with Pfizer, and will be responsible for the import and distribution
of Pfizer's nematevir tablets/ritonavir tablets (Paxlovid) in the Chinese mainland market during the agreement period.
The term of the Agreement is from December 14, 2022 to November 30, 2023, unless terminated
earlier in accordance with the Agreement.
China National Pharmaceutical said that the final use and sales of products are affected by the epidemic and other factors
.
The agreement is the daily operation of the company, the implementation of the agreement will not affect the independence of the company's business, and the company's main business will not rely on
the other party to the agreement for such transactions.
At 10:13 on December 16, Lingkang Pharmaceutical opened the intraday limit and is now quoted at 7.
03 yuan, with a transaction of 130 million yuan and a turnover rate of 2.
64%.

It is reported that the stock has risen 4 times
in the past year.
According to the data, Lingkang Pharmaceutical Co.
, Ltd.
is mainly engaged in the research and development, production and sales of prescription chemical drugs, and its main products are cardiovascular and cerebrovascular products (Huperzine A for injection, nicergoline for injection, etc.
).

The company has become an enterprise
in the domestic chemical preparation industry.
The company has obtained a total of 109 varieties and a total of 191 drug production approval documents, of which 48 varieties have been listed in the national medical insurance catalogue and 13 varieties have been listed in the national basic drug list
.
At 9:43 on December 16, Zhongsheng Pharmaceutical rose intraday to 35.
33 yuan, and the current closed order is 229929 lots, equivalent to 812 million yuan
.
It is reported that since late September 2022, the stock price of Zhongsheng Pharmaceutical has risen sharply continuously, from a low of 11.
88 yuan to 41.
3 yuan, the largest increase of 248% in two months, on the news, the RAY1216 developed by Zhongsheng Pharmaceutical and Paxlovid belong to the same 3CL protease technology route
.
Huaxin Securities research report believes that RAY1216 has the potential to become an antiviral drug and is expected to become the main national and local reserve drugs
.
It is reported that RAY1216 developed by Zhongsheng Pharmaceutical has just entered clinical phase
III.
Guosheng Securities research report predicts that the phase III clinical trial of RAY1216 is expected to be completed in 2023 and approved for marketing
in 2024.
Zhongsheng Pharmaceutical said that RAY1216 is a powerful and broad-spectrum 3CL protease inhibitor with global independent intellectual property rights, and the company will continue to promote clinical research
with high quality, rapidity and science in accordance with relevant requirements.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.